金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01548 金斯瑞生物科技

未开盘 11-18 16:08:08

10.660

-0.840

-7.30%

最高11.660	最低10.560	成交量2,585万
今开11.560	昨收11.500	日振幅9.57%
总市值226.89亿	流通市值226.89亿	总股本21.28亿
成交额2.80亿	换手率1.21%	流通股本21.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":10.66,"timestamp":1731917288015,"preClose":11.5,"halted":0,"volume":25845745,"delay":0,"floatShares":2128455268,"shares":2128455268,"eps":-0.35232624,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.84,"latestTime":"11-18 16:08:08","open":11.56,"high":11.66,"low":10.56,"amount":279619539,"amplitude":0.095652,"askPrice":10.66,"askSize":236000,"bidPrice":10.64,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.6518459706232632,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1451404800000,"adjPreClose":11.5,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":1.430095,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548/tweets","defaultTab":"tweets","newsList":[{"id":"2484624148","title":"金斯瑞生物科技(01548)因期权获行使而发行418万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484624148","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484624148?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:47","pubTimestamp":1731934074,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，该公司于2024年11月18日根据2015年7月15日通过的上市前股份期权计划行使的股份期权而发行418万股。此外，于2024年11月14日，该公司根据2015年12月7日通过的上市后股份期权计划行使的股份期权发行2万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","BK1141","01548","HK0000320223.HKD","HK0000306685.HKD","BK1583","BK1576","HK0000306701.USD"],"gpt_icon":0},{"id":"2484664498","title":"金斯瑞生物科技(01548)下跌5.22%，报10.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484664498","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484664498?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:55","pubTimestamp":1731894908,"startTime":"0","endTime":"0","summary":"11月18日，金斯瑞生物科技(01548)盘中下跌5.22%，截至09:55，报10.9元/股，成交5126.34万元。金斯瑞生物科技股份有限公司是全球的生命科学研发与生产服务提供商，以DNA合成技术为基础，主要服务包含生命科学服务及产品业务、生物制剂合约开发及生产、工业合成产品业务、以及综合性全球细胞疗法。至2024年6月30日，公司全球拥有超过6900名员工，已有超103,600篇学术期刊引述了其服务及产品，拥有超过300项授权专利与900多项专利申请，并积极致力于成为全球最受信赖的生物科技公司。截至2024年中报，金斯瑞生物科技营业总收入40.01亿元、净利润-12.48亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18095545386969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","HK0000320223.HKD","HK0000306701.USD","HK0000320264.USD","BK1576","HK0000306685.HKD","01548","BK1583"],"gpt_icon":0},{"id":"2483624345","title":"金斯瑞生物科技11月15日获主力加仓5006万元 环比增加1094.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483624345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483624345?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:16","pubTimestamp":1731658599,"startTime":"0","endTime":"0","summary":"11月15日, 金斯瑞生物科技股价涨6.28%，报收11.50元，成交金额4.21亿元，换手率1.70%，振幅9.43%，量比2.02。金斯瑞生物科技今日主力资金净流入5006万元，连续5日净流入，上一交易日主力净流入419万元，今日环比增加1094.75%。该股近5个交易日上涨5.33%，主力资金累计净流入7011万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1364万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161711abc3e081&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161711abc3e081&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","01548","HK0000320223.HKD","HK0000306685.HKD","BK1583","HK0000306701.USD","HK0000320264.USD"],"gpt_icon":0},{"id":"2483167399","title":"金斯瑞生物科技(01548)上涨10.17%，报11.92元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483167399","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483167399?lang=zh_cn&edition=full","pubTime":"2024-11-15 11:33","pubTimestamp":1731641608,"startTime":"0","endTime":"0","summary":"11月15日，金斯瑞生物科技(01548)盘中上涨10.17%，截至11:33，报11.92元/股，成交2.52亿元。金斯瑞生物科技股份有限公司是全球的生命科学研发与生产服务提供商，以DNA合成技术为基础，主要服务包含生命科学服务及产品业务、生物制剂合约开发及生产、工业合成产品业务、以及综合性全球细胞疗法。至2024年6月30日，公司全球拥有超过6900名员工，已有超103,600篇学术期刊引述了其服务及产品，拥有超过300项授权专利与900多项专利申请，并积极致力于成为全球最受信赖的生物科技公司。截至2024年中报，金斯瑞生物科技营业总收入40.01亿元、净利润-12.48亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/15113345326747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HK0000306701.USD","HK0000320264.USD","BK1141","HK0000306685.HKD","BK1583","BK1576","01548","HK0000320223.HKD"],"gpt_icon":0},{"id":"2483393491","title":"金斯瑞生物科技(01548)股价上升8.318%，现价港币$11.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2483393491","media":"阿斯达克财经","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483393491?lang=zh_cn&edition=full","pubTime":"2024-11-15 10:55","pubTimestamp":1731639300,"startTime":"0","endTime":"0","summary":"[上升股]金斯瑞生物科技(01548) 股价在上午10:55比前收市价上升8.318%，现股价为港币$11.72。至目前为止，今日最高价为$11.72，而最低价为$11.04。总成交量为1.662千万股，总成交金额为港币$1.898亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2411151050/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1576","01548","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD","BK1141","BK1583"],"gpt_icon":0},{"id":"2483364987","title":"金斯瑞生物科技早盘涨逾3% 南京蓬勃与礼新医药科技达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483364987","media":"新浪港股","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483364987?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:42","pubTimestamp":1731634920,"startTime":"0","endTime":"0","summary":"　　金斯瑞生物科技早盘上涨2.96%，现报11.14港元，成交额4283.21万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-15/doc-incwcefu0395010.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-15/doc-incwcefu0395010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1576","01548","BK1583","HK0000320264.USD","BK1574","HK0000306685.HKD","HK0000306701.USD","BK1161","BK1141","HK0000320223.HKD","159938","BK1515"],"gpt_icon":0},{"id":"2483624313","title":"金斯瑞生物科技(01548.HK)授予礼新抗PD-1全球专利权","url":"https://stock-news.laohu8.com/highlight/detail?id=2483624313","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483624313?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:41","pubTimestamp":1731634860,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技公布，其非全资子公司南京蓬勃授予礼新独家全球可转让许可，及其有权授予再许可，使其有权针对若干披露抗PD-1 单域抗体的专利和相关专有技术进行开发、生产、商业化及以其他方式应用若干分子及包含许可分子在内的若干产品，以用于全球所有用途。同日，LaNova就经重述及经修订协议下的付款安排向蓬勃南京发出确认函，南京蓬勃及镇江蓬勃生物科将有权根据经重述及经修订协议从LaNova获得付款。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230615103405395_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230615103405395_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396892/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000320223.HKD","HK0000306685.HKD","BK1141","BK1576","BK1583","HK0000306701.USD","01548","HK0000320264.USD"],"gpt_icon":0},{"id":"2483369089","title":"金斯瑞生物科技盘中异动 急速上涨5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483369089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483369089?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:30","pubTimestamp":1731634232,"startTime":"0","endTime":"0","summary":"2024年11月15日早盘09时30分，金斯瑞生物科技股票出现异动，股价快速拉升5.91%。金斯瑞生物科技股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，迈博药业-B、百奥赛图-B、晶泰科技涨幅较大，振幅较大的相关个股有晶泰科技、科济药业-B、金斯瑞生物科技，振幅分别为7.16%、2.91%、2.40%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111509303398e42c50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111509303398e42c50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","BK1583","01548","HK0000320223.HKD","BK1141"],"gpt_icon":0},{"id":"2483369767","title":"港股异动 | 金斯瑞生物科技(01548)高开逾3% 南京蓬勃与礼新医药科技达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483369767","media":"智通财经","labels":["Company Corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483369767?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:27","pubTimestamp":1731634077,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技高开逾3%，截至发稿，涨3.51%，报11.2港元，成交额430.08万港元。同日， LaNova 就经重述及经修订协议下的付款安排向蓬勃南京发出确认函，南京蓬勃及镇江蓬勃生物科技有限公司将有权根据经重述及经修订协议从 LaNova 获得付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","159938","09939","BK1583","HK0000306685.HKD","BK1574","HK0000320223.HKD","BK1161","BK1515","HK0000320264.USD","BK1576","01548","BK1141"],"gpt_icon":0},{"id":"2483936502","title":"金斯瑞生物科技子公司与礼新达成全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483936502","media":"财中社","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483936502?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:54","pubTimestamp":1731632063,"startTime":"0","endTime":"0","summary":"财中社11月15日电金斯瑞生物科技（01548）发布公告，宣布其非全资子公司南京蓬勃生物科技有限公司与礼新医药科技有限公司于2024年11月12日达成许可协议。根据该协议，南京蓬勃将授予礼新独家全球可转让许可，涉及若干抗PD-1单域抗体的专利及相关专有技术的开发、生产和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411153240395312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","HK0000320223.HKD","HK0000306701.USD","BK1583","HK0000320264.USD","BK1576","01548","HK0000306685.HKD"],"gpt_icon":0},{"id":"2483659833","title":"金斯瑞生物科技任命Quelch博士为独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2483659833","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483659833?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:47","pubTimestamp":1731631672,"startTime":"0","endTime":"0","summary":"财中社11月15日电金斯瑞生物科技（01548）发布公告，宣布JohnAnthonyQuelch博士自2024年11月14日起被任命为公司独立非执行董事及战略委员会成员。Quelch博士在高等教育领域有超过四十年的管理经验，曾担任多所知名大学的领导职务，具备丰富的战略和品牌管理经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411153240326682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1576","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","BK1141","01548","HK0000306685.HKD"],"gpt_icon":0},{"id":"2483363482","title":"金斯瑞生物科技(01548)：南京蓬勃与礼新医药科技达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483363482","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483363482?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:34","pubTimestamp":1731630857,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 公布，于2024年11月12日，公司非全资子公司南京蓬勃生物科技有限公司与礼新医药科技有限公司(礼新)订立经重述及经修订许可协议，根据该协议，南京蓬勃同意授予礼新独家全球可转让许可，及其有权授予再许可，使其有权针对若干披露抗 PD-1单域抗体的专利和相关专有技术进行开发、生产、商业化及以其他方式应用若干分子及包含许可分子在内的若干产品，以用于全球所有用途。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","01548","09939","BK1515","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD","159938","BK1141","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2483135267","title":"金斯瑞生物科技(01548)委任John Anthony Quelch为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2483135267","media":"智通财经","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483135267?lang=zh_cn&edition=full","pubTime":"2024-11-15 07:25","pubTimestamp":1731626756,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)公布，John Anthony Quelch 博士获委任为金斯瑞生物科技股份有限公司的独立非执行董事及战略委员会成员，自2024年11月14日生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01548","HK0000306701.USD","BK1576","HK0000320223.HKD","HK0000306685.HKD","BK1141","HK0000320264.USD"],"gpt_icon":0},{"id":"2483024667","title":"金斯瑞生物科技11月13日主力资金流入447万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483024667","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483024667?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:16","pubTimestamp":1731485772,"startTime":"0","endTime":"0","summary":"11月13日，金斯瑞生物科技股价收平报10.92元，成交金额1.38亿元，换手率0.61%，振幅5.13%，量比0.74。金斯瑞生物科技今日主力资金净流入447万元，连续3日净流入，上一交易日主力净流入920万元，今日环比减少51.41%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为42.86%，平均涨幅为3.19%。该股近5个交易日下跌10.64%，主力资金累计净流出1493万元；近20日主力资金累计净流出3463万元，其中净流出天数为12日。该股主力净额占比0.02%，港股市场排名171/2644。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161640a233243a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161640a233243a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","HK0000306685.HKD","01548","HK0000306701.USD","BK1576","HK0000320223.HKD","HK0000320264.USD","BK1141"],"gpt_icon":0},{"id":"2483809019","title":"【港股通】金斯瑞生物科技跌3.85% 旗下传奇生物Q3净亏损1.253亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809019","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483809019?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:57","pubTimestamp":1731466627,"startTime":"0","endTime":"0","summary":"金吾财讯 | 金斯瑞生物科技 股价受压，截止发稿，跌3.85%，报10.5港元，成交额7631万港元。消息面上，金斯瑞生物科技公布传奇生物2024年第三季度业绩，CARVYKTI净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长53.2%。净亏损为1.253亿美元，2023年同期为6220万美元。需要注意的是，日前，金斯瑞发布公告称，传奇生物的财务业绩不再合并入公司财务报表。该行预计，在净利润层面，2024年起金斯瑞将全面进入盈利区间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113105745abbbbce0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113105745abbbbce0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","BK1576","LEGN","HK0000306685.HKD","BK1583","01548","HK0000320264.USD","HK0000320223.HKD","BK1141","HK0000306701.USD","HSCEI"],"gpt_icon":0},{"id":"2483151100","title":"港股异动 | 金斯瑞生物科技(01548)早盘跌近5% 传奇生物第三季度亏损扩大至1.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483151100","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483151100?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:39","pubTimestamp":1731465568,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技早盘跌近5%，截至发稿，跌4.4%，报10.44港元，成交额6556.92万港元。消息面上，金斯瑞生物科技公布传奇生物2024年第三季度业绩，CARVYKTI净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长53.2%。净亏损为1.253亿美元，2023年同期为6220万美元。值得注意的是，金斯瑞此前发布公告称，传奇生物的财务业绩不再合并入公司财务报表，公司将其视为对联营公司的投资。预计2024年起金斯瑞将全面进入盈利区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1583","HK0000306685.HKD","01548","BK4505","HK0000306701.USD","LEGN","BK1576","BK4588","HK0000320223.HKD","BK4585","HK0000320264.USD","BK1141"],"gpt_icon":0},{"id":"2483092490","title":"金斯瑞生物科技11月12日遭南向资金减持317.80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092490","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483092490?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461413,"startTime":"0","endTime":"0","summary":"11月12日，南向资金减持金斯瑞生物科技317.80万股。截止当日收盘，港股通共持有金斯瑞生物科技50015.56万股，占流通股23.48%。金斯瑞生物科技近5个交易日下跌9.75%，港股通累计增持37.20万股；近20个交易日下跌8.54%，港股通累计增持2230.36万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093132abbb7ee5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093132abbb7ee5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","HK0000320264.USD","BK1583","HK0000320223.HKD","HK0000306701.USD","HK0000306685.HKD","01548","BK1576"],"gpt_icon":0},{"id":"2483096594","title":"传奇生物(LEGN.US)第三季净亏损按年扩大至1.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483096594","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483096594?lang=zh_cn&edition=full","pubTime":"2024-11-13 08:24","pubTimestamp":1731457440,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技公布，其持有47.56%的联营公司传奇生物第三季录得净亏损1.25亿美元，去年同期亏损6,220万美元。期内，传奇生物的许可证收入为1,710万美元，全部来自与诺华的许可协议；而去年同期许可收入为2,010万美元，全部来自杨森协议下里程碑的达成。传奇生物第三季的合作收入为1.43亿美元，去年同期为7,590万美元，增长主要由于与杨森协议有关的CARVYKTI销售收入增加。截至9月30日，传奇生物的现金及现金等价物和定期存款为12亿美元。沽空资料截至 2024-11-12 16:25。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180509171357768_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180509171357768_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396163/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","HK0000320223.HKD","HK0000306701.USD","BK1583","HK0000320264.USD","BK1576","01548","HK0000306685.HKD"],"gpt_icon":0},{"id":"2483647040","title":"金斯瑞生物科技：传奇生物三季度合作收入为1.428亿美元 同比增长88.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483647040","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483647040?lang=zh_cn&edition=full","pubTime":"2024-11-13 07:18","pubTimestamp":1731453480,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技（01548）公布传奇生物2024年第三季度业绩， CARVYKTI （西达基奥仑赛；cilta-cel）净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。 合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI®销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。\n　　截至2024年9月30日，现金及现金等价物和定期存款达到12亿美元，传奇生物认为这些资金将提供直至2026年的财务储备，传奇生物预计在 2026年实现经营利润。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-13/doc-incvwmtt1507400.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-13/doc-incvwmtt1507400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1576","01548","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD","BK1141","BK1583"],"gpt_icon":0},{"id":"2483129066","title":"金斯瑞生物科技(01548)：传奇生物三季度合作收入为1.428亿美元，同比增长88.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483129066","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483129066?lang=zh_cn&edition=full","pubTime":"2024-11-13 06:20","pubTimestamp":1731450019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 公布传奇生物2024年第三季度业绩， CARVYKTI 净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。截至2024年9月30日，现金及现金等价物和定期存款达到12亿美元，传奇生物认为这些资金将提供直至2026年的财务储备，传奇生物预计在 2026年实现经营利润。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LEGN","BK1141","HK0000320223.HKD","HK0000306701.USD","BK1583","HK0000306685.HKD","HK0000320264.USD","BK4588","BK1576","BK4139","01548","BK4505","BK4585"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0309},{"period":"1month","weight":-0.119},{"period":"3month","weight":-0.1499},{"period":"6month","weight":-0.0649},{"period":"1year","weight":-0.5493},{"period":"ytd","weight":-0.4632}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"制造及销售生命科学研究产品及服务。产品及服务主要包括生命科学研究服务、临床前药物研发服务、生命科学研究目录产品及工业合成生物产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.012915},{"month":2,"riseRate":0.555556,"avgChangeRate":0.078892},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.061679},{"month":4,"riseRate":0.555556,"avgChangeRate":0.055583},{"month":5,"riseRate":0.444444,"avgChangeRate":0.056395},{"month":6,"riseRate":0.555556,"avgChangeRate":0.032355},{"month":7,"riseRate":0.555556,"avgChangeRate":0.066374},{"month":8,"riseRate":0.333333,"avgChangeRate":0.112385},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.076829},{"month":10,"riseRate":0.666667,"avgChangeRate":0.110695},{"month":11,"riseRate":0.666667,"avgChangeRate":0.057205},{"month":12,"riseRate":0.375,"avgChangeRate":0.084334}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}